Pfizer’s COVID-19 pill Paxlovid won another vote of confidence from U.S. health advisers, clearing the way for its full approval by the FDA. The medication has been used by millions of Americans since it was granted emergency use authorization in 2021.
emergency use authorization
in late 2021. The agency has the final say on giving Pfizer’s drug full approval and is expected to decide by May. A panel of outside experts voted 16-1 that Paxlovid remains a safe and effective treatment for high-risk adults with COVID-19 who are more likely to face hospitalization and death due to the virus.
“We still have many groups that stand to benefit from Paxlovid, including unvaccinated persons, under-vaccinated persons, the elderly and the immuno-compromised,” said Dr. Richard Murphy of the Department of Veterans Affairs. The FDA said using Paxlovid in high-risk patients could prevent 1,500 COVID-19 deaths and 13,000 hospitalizations per week.The panel’s positive vote was widely expected, given that Paxlovid has been the go-to treatment against COVID-19, especially since an entire group ofThe U.S. continues reporting about 4,000 deaths and 35,000 hospitalizations weekly, the FDA noted.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
FDA: Paxlovid Does Not Cause COVID ‘Rebound’The FDA says in a new report that rebound also occurs in people who did not take paxlovid—which can prevent COVID from becoming severe if given early enough—and appears to be part of the disease process in some.
Leer más »
FDA: Paxlovid not associated with COVID reboundPaxlovid isn't associated with COVID rebound, in which patients test positive or have symptoms days after a course of the drug is completed, Food and Drug Administration staff said Tuesday.
Leer más »
No clear association between Paxlovid and COVID-19 rebound, FDA saysAn FDA analysis did not find a clear association between the COVID-19 antiviral drug Paxlovid and illness rebound, the FDA said in a new report.
Leer más »
Paxlovid not linked to COVID rebound, FDA saysClinical trial data has concluded that there is no clear association with a COVID-19 rebound.
Leer más »
Paxlovid not linked to COVID rebound, FDA saysThe FDA gave the COVID-19 anti-viral emergency use authorization in 2021 for treating mild to moderate illness in high-risk adults.
Leer más »
COVID-19 pill Paxlovid moves closer to full FDA approvalU.S. health advisersare backing the continued use of Pfizer’s COVID-19 pill Paxlovid, saying it remains an important option for adults at high risk of severe illness
Leer más »